Form 4: Glaukos Director Marc Stapley Receives RSU Grant

Glaukos Corporation's Director, Marc Stapley, was granted 727 restricted stock units as part of the company's Director Compensation Policy.

Summary

• Marc Stapley, a Director at Glaukos Corporation (GKOS), was granted 727 shares of common stock in the form of restricted stock units (RSUs).
• The transaction date for this grant was January 2, 2026.
• These restricted stock units were granted at a price of $0 per unit, consistent with a compensation grant.
• The RSUs are scheduled to vest in full on the one-year anniversary of the grant date, which is January 2, 2027.
• Following this transaction, Marc Stapley beneficially owns 37,449 shares of Glaukos common stock.
• The total beneficial ownership includes 2,835 restricted stock units that have not yet vested or been delivered, as well as vested RSUs where delivery has been deferred.

Sentiment

Score: 6

Explanation: The filing reports a routine compensation grant to a director, which is a neutral to slightly positive event as it aligns management interests with shareholders. It does not indicate any significant operational or financial performance changes.

Positives

• The grant of restricted stock units to Director Marc Stapley aligns his interests with those of the company's shareholders, as the value of his compensation is tied to the company's stock performance.
• This transaction is part of the Issuer's Director Compensation Policy, indicating a structured approach to executive and director remuneration.

Future Outlook

The 727 restricted stock units granted to Director Marc Stapley are scheduled to vest in full on January 2, 2027, which is the one-year anniversary of the grant date.

Industry Context

The grant of restricted stock units to a director is a common practice in publicly traded companies across various industries. This form of equity compensation is widely used to attract, retain, and incentivize directors by aligning their financial interests with the long-term performance of the company and its shareholders.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) as part of director compensation is a standard practice, comparable to compensation structures seen at peer companies in the medical device and ophthalmology sectors.
• The vesting schedule of one year is typical for such grants, aiming to provide a balance between immediate incentive and long-term commitment, similar to practices at companies like Alcon (ALC) or Bausch + Lomb (BLCO) for their non-employee directors.

Related Party Transactions

• The grant of 727 restricted stock units to Marc Stapley, a Director of Glaukos Corporation, constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial incentives with shareholder value creation, potentially fostering long-term strategic decisions.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The 727 restricted stock units will vest on January 2, 2027, at which point they will be convertible into an equivalent number of shares of Glaukos common stock.

Key Dates

Keywords

Glaukos, GKOS, Marc Stapley, Restricted Stock Units, RSU Grant, Director Compensation, Insider Transaction, SEC Form 4